Amgen and Novartis may have won the race to launch the first FDA-approved migraine drug with Aimovig, but rivals Teva and Eli Lilly are working on their versions this year.
BioSpace reported that the U.S. Food and Drug Administration (FDA) gave the green signal to produce Aimovig after Phase III data showed it can reduce monthly migraine attacks by as much as 50 percent. Amgen and Novartis produced the said drug, and the recent development is nothing short of an accomplishment for the two pharma companies. Other companies involved in making migraine drugs are Allergan, Teva, Eli Lilly and Alder BioPharmaceuticals.
Aimovig reduces migraine attacks by blocking the calcitonin gene-related peptide receptor, which is a major factor in causing migraine and cluster headaches. Episodic migraines attack almost 14 days every month, and patients who used Aimovig showed reductions in such attacks. In the U.S., there is an estimate of 4 million people suffering from migraines at least 15 days monthly.
Amgen Research and Development head Sean Harper said that a migraine can cause more devastating effects than what was originally believed. “The FDA approval of Aimovig represents a long-awaited and important therapeutic development for patients and their physicians who are in need of additional treatment options for the prevention of migraine,” he added.
Aimovig is administered once a month via Amgen’s SureClick autoinjector. A single shot will be available in doses of 70 or 140 mg and will cost at least $575 for each injection. Due to insurance, patients can pay as low as $5 for Aimovig. The drugmakers are also offering a two-month free trial for new patients to offset the high annual price tag of $6,900.
While the approval of Aimovig is indeed historic, there is still unknown information about the drug. Lifehacker notes that it remains to be seen if the said drug is safe for pregnant or breastfeeding women. Also, its effects on liver toxicity, heart attacks, and stroke have yet to be studied. As such, the advice of health professionals and exercise of due diligence are still important. After all, the effect on people may still vary.
On the other hand, Teva is also producing its own migraine drug, per CNBC. The company announced it is targeting a September 2018 release date for fremanezumab, its own migraine drug. Joining the race is Eli Lilly, which also plans to launch its own medicine called galcanezumab this year.
Teva had the chance to launch fremanezumab ahead of Aimovig, but the FDA approval was delayed amid manufacturing facility issues in one of Teva’s partners in South Korea. “Our primary goal is to bring preventive treatment options to migraine patients as quickly as possible. We are encouraged by the ongoing communications with the FDA as we work to bring this important therapy to patients,” Teva’s global R&D executive vice president Hafrun Fridriksdottir explained.
Meanwhile, Eli Lilly’s galcanezumab is anticipated to receive a decision from the FDA by Q3 2018.
Teva is pinning its hopes on fremanezumab to help turn things around as the pharma company is saddled with $35 billion in debt. As of March, Teva’s gross debt remained at $30.8 billion.
Why a college concierge matters
A college concierge with a variety of services can give college students a reprieve amid their busy schedules at schools...
Why you should make catch-up contributions to your retirement plan
Sometimes people are unable to contribute regularly to their retirement plans. However, they can still make catch-up contributions. Here's why...
MGM Resorts International bags partnership deal with MLB
MGM Resorts International is now the first official gaming and entertainment partner of Major League Baseball.
Google’s latest expansion plans include affordable housing
Google's latest development plans for Mountain View, California, combine a mix of office, retail, public space and housing, with affordable...
Here’s why you should pack the right travel socks
Traveling involves a lot of walking. Apart from wearing the right shoes, it’s also important that you protect your feet...
Auto5 days ago
Ford, VW discuss potential partnership after White House meeting
Business5 days ago
Select cannabis companies continue to flourish amid market downtrend
Business4 days ago
Here’s why personal space is a vanishing commodity on airplanes
Auto4 days ago
8 reasons why bike-sharing startups are attracting investors
Featured2 days ago
How singles should plan for retirement
Business4 days ago
Earthquake highlights need to overhaul Port of Alaska
Business3 days ago
India’s tech scene brings in foreign investments
Featured3 days ago
How to manage your 401(k) plan in a time of market volatility